Patricia Inacio, PhD, science writer —

Patricia holds her PhD in cell biology from the University Nova de Lisboa, Portugal, and has served as an author on several research projects and fellowships, as well as major grant applications for European agencies. She also served as a PhD student research assistant in the Department of Microbiology & Immunology, Columbia University, New York, for which she was awarded a Luso-American Development Foundation (FLAD) fellowship.

Articles by Patricia Inácio

Ear, nose, throat symptom relapses common in AAV, despite treatment

Despite high response rates to treatment strategies to reduce ear, nose, and throat involvement in ANCA-associated vasculitis (AAV), relapses are common, a review study reports. The study, “Systemic and Local Medical or Surgical Therapies for Ear, Nose and/or Throat Manifestations in ANCA-Associated Vasculitis: A Systematic Literature Review,” was…

New ANCA cut-off value may aid accuracy of AAV diagnosis

Researchers have proposed a new cut-off value for blood levels of anti-neutrophil cytoplasmic antibodies (ANCAs) to improve the accuracy of ANCA-associated vasculitis (AAV) diagnosis. Using this cut-off value, researchers could accurately distinguish AAV from other diseases also characterized by inflammation and damage to small blood vessels. “This study provides a…

Tavneos approved in Australia as add-on therapy for GPA, MPA

Tavneos (avacopan) has been approved in Australia as an add-on oral therapy for adults with two main types of ANCA-associated vasculitis (AAV): microscopic polyangiitis (MPA) and granulomatosis polyangiitis (GPA). The approval from Australia’s Therapeutic Goods Administration specifically covers the use of Tavneos in combination with rituximab or…

Cyclophosphamide Plus Rituximab Prevents AAV Relapses: Study

Adding a low dose of cyclophosphamide to rituximab for remission induction was safe and more effective at preventing relapses in the first two years in people with severe ANCA-associated vasculitis (AAV) than rituximab alone, a new study shows. No significant benefit was observed in the combination treatment after five years.

Case Links Pfizer-BioNTech COVID Vaccine to AAV Kidney Damage

A woman developed a rare case of acute kidney failure linked to ANCA-associated vasculitis (AAV) following her first dose of the Pfizer-BioNTech COVID-19 vaccine, according to a report. This case adds to previous reports suggesting that COVID-19 vaccines may, in rare instances, promote the development or exacerbation of autoimmune…